# Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

> **NCT00168051** · PHASE4 · WITHDRAWN · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** ReFacto
- **DRUG:** Advante

## Key facts

- **NCT ID:** NCT00168051
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-04
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168051, "Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00168051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*